China Cardiac Resynchronization Therapy Market Overview, 2031

Key Insights

• China represents one of the fastest-growing Cardiac Resynchronization Therapy (CRT) markets globally, driven by an aging population, rising cardiovascular disease burden, and expansion of advanced cardiac care infrastructure. The population aged 60 years and above has exceeded 280 million, increasing the prevalence of heart failure, ischemic cardiomyopathy, conduction disorders, and arrhythmias. Cardiovascular disease remains the leading cause of mortality in China, creating strong demand for CRT-P and CRT-D systems as more patients require long-term heart failure management solutions.
• China’s CRT market is expanding rapidly due to improving diagnosis, increasing physician awareness, and government investment in healthcare modernization. CRT adoption is concentrated in Grade III Class A hospitals, university medical centres, and cardiovascular institutes located in major cities such as Beijing, Shanghai, Guangzhou, and Shenzhen. Although access remains uneven between urban and lower-tier healthcare facilities, the country’s large untreated patient population and expanding electrophysiology capabilities provide significant growth opportunities for advanced cardiac device therapies.
• China’s cardiac device ecosystem is evolving through a combination of international expertise and domestic innovation. Global companies including Medtronic, Abbott, Boston Scientific, and BIOTRONIK maintain strong market positions, while domestic manufacturers such as MicroPort Medical and Lepu Medical Technology are expanding through localization and cost-effective solutions. Professional organizations, including the Chinese Society of Cardiology and Chinese Society of Pacing and Electrophysiology, are supporting standardized treatment practices and improving CRT adoption across the healthcare system.

Market Outlook

• According to the research report, "China Cardiac Resynchronization Therapy Market Outlook, 2031," published by Bonafide Research, the China Cardiac Resynchronization Therapy Market is anticipated to grow at more than 6.30% CAGR from 2026 to 2031.
• China’s CRT market growth will be strongly supported by national healthcare strategies such as Healthy China 2030, which emphasize cardiovascular disease prevention, early diagnosis, standardized treatment, and mortality reduction. The expansion of specialized Heart Failure Centers and Cardiovascular Disease Centres is improving patient identification and referral pathways. Integrated care models involving cardiologists, electrophysiologists, rehabilitation specialists, and primary care providers are increasing access to CRT for eligible heart failure patients.
• Digital healthcare transformation is creating new opportunities for connected CRT technologies in China. Remote monitoring platforms enable physicians to track device performance, pacing parameters, arrhythmia events, and heart failure indicators without frequent hospital visits. These solutions are particularly valuable for managing large patient populations across geographically diverse regions and improving long-term follow-up care, especially for patients outside major metropolitan areas.
• China’s CRT market is also being shaped by healthcare cost-control reforms and domestic medical technology development initiatives. Procurement reforms led by the National Healthcare Security Administration are increasing price competition and improving device affordability. Meanwhile, localization policies are encouraging domestic manufacturers to develop advanced cardiac technologies, strengthening supply chains and increasing competition with established international companies.

Market Dynamics

Driver: Increasing cardiovascular disease burden and expansion of advanced cardiac care infrastructure
China’s growing cardiovascular disease burden is the primary factor driving CRT market expansion. Rising prevalence of hypertension, diabetes, obesity, and improved survival after cardiovascular events are increasing the number of patients with chronic heart failure. With an aging population and higher life expectancy, demand is growing for advanced therapies that improve cardiac function, reduce hospitalizations, and enhance quality of life among eligible heart failure patients.
Expansion of cardiovascular infrastructure is further supporting CRT adoption across China. Investments in Grade III Class A hospitals, cardiovascular centres, catheterization laboratories, and electrophysiology departments are improving implantation capabilities. Government healthcare reforms are also strengthening referral networks between primary facilities, regional centres, and advanced hospitals, gradually increasing access to CRT procedures beyond major metropolitan areas.

Challenge: Unequal access, cost sensitivity, and limited CRT penetration outside major urban centres
China’s CRT market continues to face challenges due to uneven distribution of specialized cardiac expertise and advanced healthcare infrastructure. Most CRT procedures are performed in major urban hospitals, while lower-tier hospitals in rural and western regions often lack trained electrophysiologists, advanced facilities, and implantation capabilities. These regional differences create disparities in diagnosis, treatment access, and long-term patient management.
Cost sensitivity remains another major barrier affecting CRT adoption. Although China’s healthcare insurance system provides broad coverage, reimbursement levels and patient expenses vary across regions. The high cost of implantable cardiac devices can limit accessibility for some patients. Additionally, procurement reforms are increasing price competition, requiring manufacturers to balance advanced technology development with affordability.

Trend: Localization of cardiac devices and expansion of digital heart failure management
China is increasingly focusing on domestic development of cardiac devices as part of its medical technology localization strategy. Government support for innovation is encouraging local manufacturers to invest in implantable cardiac rhythm management systems, remote monitoring technologies, and advanced electrophysiology solutions. This trend is expected to increase competition, improve supply chain stability, and enhance accessibility of CRT technologies.
Digital healthcare transformation is becoming a key trend in China’s CRT market. Hospitals are adopting remote monitoring, electronic health records, artificial intelligence tools, and telemedicine platforms to improve chronic heart failure management. Connected CRT devices enable continuous tracking of pacing performance, arrhythmias, and heart failure indicators, supporting personalized care and reducing dependence on frequent hospital visits.

Policies

• National Medical Products Administration (NMPA) Medical Device Regulation: Cardiac Resynchronization Therapy systems marketed in China are regulated by the National Medical Products Administration (NMPA) under China’s medical device regulatory framework. CRT devices are classified as high-risk implantable medical devices requiring strict evaluation of safety, clinical performance, quality management systems, and post-market surveillance before commercial approval.
• Medical Device Localization and Innovation Policies: China has implemented multiple government initiatives encouraging domestic medical device development and reducing dependence on imported technologies. Policies supporting indigenous innovation, domestic manufacturing capability, and advanced medical technology development are influencing the competitive structure of the cardiac device industry.
• National Healthcare Security Administration (NHSA) Reimbursement Framework: CRT implantation procedures are primarily financed through China’s public insurance system, including Urban Employee Basic Medical Insurance (UEBMI) and Urban-Rural Resident Basic Medical Insurance (URRBMI). Reimbursement policies vary by province and influence patient affordability, hospital adoption, and device procurement decisions.
• Volume-Based Procurement and Healthcare Cost Control Policies: China’s medical device procurement reforms, led by the NHSA and provincial governments, aim to reduce healthcare costs through centralized purchasing mechanisms. While historically focused on consumable medical products, these reforms are increasingly influencing pricing strategies, supplier competition, and hospital purchasing decisions for advanced medical technologies.
• Healthy China 2030 Cardiovascular Health Strategy: The Healthy China 2030 framework prioritizes prevention, early detection, standardized treatment, and improved management of chronic diseases including cardiovascular disorders. These initiatives support expansion of heart failure programmes, cardiovascular screening, specialist training, and access to advanced therapeutic technologies.
• Clinical Governance and Professional Guidelines: CRT adoption in China is supported by recommendations from the Chinese Society of Cardiology (CSC), Chinese Society of Pacing and Electrophysiology (CSPE), and alignment with international standards including ESC guidelines. These organizations contribute to physician education, standardized implantation practices, clinical research, and quality improvement initiatives across China’s cardiovascular healthcare system.

Segment Analysis

China Cardiac Resynchronization Therapy Market By Product Type • CRT-D (Cardiac Resynchronization Therapy Defibrillator) represents the leading product segment in China due to its combined capability of ventricular resynchronization and sudden cardiac death prevention. Demand is primarily driven by patients with heart failure with reduced ejection fraction (HFrEF), ischemic cardiomyopathy, dilated cardiomyopathy, left bundle branch block (LBBB), and high ventricular arrhythmia risk.
• Adoption of CRT-D is concentrated in Grade III Class A hospitals, national cardiovascular centres, and university hospitals located in Beijing, Shanghai, Guangzhou, Shenzhen, Chengdu, and other major cities. Institutions such as Fuwai Hospital, Beijing Anzhen Hospital, and Zhongshan Hospital play an important role in advanced electrophysiology procedures, physician training, and clinical research.
• China’s CRT-D penetration remains lower compared with developed markets, creating significant growth potential. Expansion of heart failure clinics, improved patient screening, increasing electrophysiology expertise, and better referral networks are expected to accelerate adoption.The CRT-D market is led by international manufacturers including Medtronic, Abbott, Boston Scientific, BIOTRONIK, and MicroPort CRM, while domestic companies are gradually strengthening their position through localization strategies and cost-effective technologies.
• CRT-D device procurement prices in China generally range between RMB 120,000–250,000 (USD 17,000–35,000) depending on manufacturer, device features, monitoring capabilities, and hospital procurement agreements.
• CRT-P (Cardiac Resynchronization Therapy Pacemaker) remains important among elderly patients and individuals requiring resynchronization therapy without defibrillation protection. Increasing life expectancy and a growing elderly population are supporting demand for CRT-P devices, particularly among patients with lower arrhythmic risk.
• CRT-P systems generally range between RMB 50,000–120,000 (USD 7,000–17,000) depending on technology and procurement conditions. Cost optimization initiatives and domestic device development are expected to support future adoption.

China Cardiac Resynchronization Therapy Market By Application

• Heart Failure Management represents the largest application segment due to China’s growing chronic heart failure burden. With an estimated 13–16 million heart failure patients, aging demographics and increasing cardiovascular disease prevalence continue to expand demand for advanced therapies.
• China is increasingly developing integrated heart failure management programmes combining cardiology, electrophysiology, rehabilitation, and remote monitoring. These models aim to reduce hospital readmissions and improve long-term patient outcomes.Remote monitoring-enabled CRT systems are gaining importance as hospitals adopt digital healthcare solutions to manage large patient populations across geographically diverse regions.
• Arrhythmia Management supports CRT-D demand due to increasing prevalence of atrial fibrillation, ventricular arrhythmias, and conduction disorders. Leading electrophysiology centres are integrating CRT implantation with catheter ablation, rhythm monitoring, and advanced programming technologies.
• Others include pacemaker upgrades, pacing-induced cardiomyopathy, congenital heart disease, and clinical research activities involving next-generation pacing technologies.

China Cardiac Resynchronization Therapy Market By End User

• Hospitals represent the largest end-user segment as CRT implantation requires specialized electrophysiology laboratories, trained specialists, advanced imaging facilities, and long-term follow-up capabilities. Most procedures are performed in tertiary Grade III hospitals.Large cardiovascular hospitals in Beijing, Shanghai, Guangdong, and Zhejiang act as referral centres for complex CRT procedures and physician training. Government investment in hospital modernization is improving access to advanced cardiac therapies.
• Cardiac Specialty Centers are expanding rapidly as China develops dedicated cardiovascular institutions focused on electrophysiology, heart failure treatment, device implantation, and clinical research.
• Others include outpatient cardiology clinics, rehabilitation facilities, and academic institutions involved in post-implant monitoring and cardiovascular research.

Market Landscape and Commercial Ecosystem

• China represents one of the fastest-growing cardiovascular device markets globally, supported by increasing healthcare expenditure, aging population, and government initiatives such as Healthy China 2030.The CRT market remains dominated by global manufacturers including Medtronic, Abbott, Boston Scientific, and BIOTRONIK, which benefit from strong clinical evidence, advanced technology portfolios, and established hospital relationships.
• Domestic companies such as MicroPort Medical and other Chinese medical technology manufacturers are expanding their presence through government-supported localization strategies and competitive pricing models.
• Healthcare procurement reforms led by the National Healthcare Security Administration (NHSA) are increasing price competition and encouraging manufacturers to demonstrate clinical value, affordability, and long-term patient outcomes.
• Digital cardiovascular care is expected to become a major growth driver, with increasing adoption of remote monitoring, telemedicine, artificial intelligence-based analytics, and connected implantable cardiac devices.
• By 2031, China is expected to become one of the largest CRT growth markets in Asia-Pacific, supported by rising heart failure prevalence, healthcare infrastructure expansion, domestic innovation, and increasing adoption of technology-enabled cardiac care models.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Cardiac Resynchronization Therapy Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product Type
• CRT-D (Cardiac Resynchronization Therapy Defibrillator)
• CRT-P (Cardiac Resynchronization Therapy Pacemaker)

By Application
• Heart Failure Management
• Arrhythmia Management
• Others

By End-User
• Hospitals
• Cardiac Specialty Centers
• Others